Teva and Lonza announce to discontinue Biologics Joint Venture

29-Jul-2013 - Switzerland

Teva Pharmaceutical Industries and Lonza Group announced that following a strategic review of the Teva-Lonza Joint Venture (TL-JV), the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars. The discontinuation of the TL-JV, which began in 2009, will enable both companies to better advance their own strategies and efforts in serving those healthcare communities. Both companies will continue to explore opportunities to maximize the value of the investments and progress that the joint venture has made to this point, and remain in agreement that affordable, efficacious and safe biosimilar treatments will bring benefits to patients and better serve these communities.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Opening the cavity floodgates - Biochemists investigate the transport of large proteins through bacterial cell membranes

Opening the cavity floodgates - Biochemists investigate the transport of large proteins through bacterial cell membranes

Watermelon genome decoded - Decoded genome paves way for better watermelons

BIO White Paper Dispels Over-Patenting Myth - Patenting is a Critical Element in Fostering Research and Development

Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation

Cells stop dividing when this gene kicks into high gear

Cells stop dividing when this gene kicks into high gear

Targeted test for antibiotic resistance in clinical Enterobacter species - New discovery enables targeted antibiotic therapy

Targeted test for antibiotic resistance in clinical Enterobacter species - New discovery enables targeted antibiotic therapy

Varian, Inc. Announces Unique Probe Technology Breakthrough for Biological Solids NMR

Breakthrough Discovery Sheds Light on Heart and Muscle Health - Scientists shoot first true-to-life 3D image of the thick filament of mammalian heart muscle

Breakthrough Discovery Sheds Light on Heart and Muscle Health - Scientists shoot first true-to-life 3D image of the thick filament of mammalian heart muscle

Diagnosis just a breath away with new laser

MIT nanotubes sniff out cancer agents in living cells - Chemical engineers use carbon nanotubes to monitor chemotherapy, detect toxins at the single-molecule level

Fishing for DNA to measure biodiversity - Identifying the fish species present in a river based on traces of their DNA: this method has been successfully tested at about 90 sites in Switzerland

Fishing for DNA to measure biodiversity - Identifying the fish species present in a river based on traces of their DNA: this method has been successfully tested at about 90 sites in Switzerland

BioTek Receives European Patent for Microplate Washer Technology